Physician profile
Maria Lauer
NPI 1548782824
$1,561.72
in general payments reported to CMS, 2019-2025
10 companies · $687 in 2025
The $687 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $138 · 2023: $20.51 · 2024: $716 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,294 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,294.32 |
| Education | $129.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $801.15 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $331.91 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $159.22 | 2021-2025 | Fasenra, Airsupra |
| Organon LLC | $67.31 | 2025 | Vtama |
| Genentech USA, INC. | $49.19 | 2024-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $48.24 | 2021-2024 | Takhzyro |
| Teva Pharmaceuticals USA, INC. | $34.82 | 2021 | |
| Amgen INC. | $31.66 | 2024 | Tezspire |
| Alk-Abello, INC | $23.32 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.90 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Lauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.